OverviewSuggest Edit

Myriad Genetics is a molecular diagnostic company which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The Company offers molecular diagnostic tests, including DNA sequencing tests for hereditary breast, ovarian, colorectal and uterine cancer, a protein quantification test for assessing the disease activity of rheumatoid arthritis, RNA expression tests for assessing the aggressiveness of prostate cancer, diagnosing melanoma, and a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. It also provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries, and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis.
TypePublic
Founded1991
HQSalt Lake City, UT, US
Websitemyriad.com
Employee Ratings3.7
Overall CultureB

Latest Updates

Employees (est.) (Jun 2019)2,600(+9%)
Job Openings143
Revenue (FY, 2020)$299.8 M(-64%)
Share Price (Jun 2021)$29.3(+7%)
Cybersecurity ratingCMore

Key People/Management at Myriad Genetics

Bryan Riggsbee

Bryan Riggsbee

Interim President and CEO, Chief Financial Officer
Paul J. Diaz

Paul J. Diaz

President and CEO
Patrick Burke

Patrick Burke

Executive Vice President, Emerging Products
Raymond Francot

Raymond Francot

Executive Vice President, International Operations
Bryan Dechairo

Bryan Dechairo

Officer, Executive Vice President, Development
Clivetty Martinez

Clivetty Martinez

Chief Compliance Officer
Show more

Myriad Genetics Office Locations

Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations
Salt Lake City, UT, US (HQ)
320 Wakara Way
Austin, TX, US
3300 Duval Rd
South San Francisco, CA, US
180 Kimball Way
South San Francisco, CA, US
341 Oyster Point Blvd
Issy-les-Moulineaux, FR
41 Rue Camille Desmoulins
Martinsried, DE
Bunsenstrasse 7
Show all (13)

Myriad Genetics Financials and Metrics

Myriad Genetics Revenue

Myriad Genetics's revenue was reported to be $299.8 m in FY, 2020
USD

Revenue (Q1, 2021)

173.1m

Net income (Q1, 2021)

(39.5m)

EBIT (Q1, 2021)

(46.7m)

Market capitalization (7-Jun-2021)

2.3b

Closing stock price (7-Jun-2021)

29.3

Cash (31-Mar-2021)

148.9m

EV

2.3b
Myriad Genetics's current market capitalization is $2.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

771.4m772.6m851.1m299.8m

Revenue growth, %

4%0%10%

Cost of goods sold

171.2m177.2m201.0m

Gross profit

600.2m595.4m650.1m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

190.2m194.0m193.5m202.3m216.8m216.6m186.3m195.1m173.1m

Cost of goods sold

43.0m44.4m44.1m49.7m52.1m48.6m49.7m49.6m

Gross profit

147.2m149.6m149.4m152.6m164.7m168.0m136.6m145.5m

Gross profit Margin, %

77%77%77%75%76%78%73%75%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

102.4m110.9m93.2m171.7m

Accounts Receivable

105.6m98.3m133.9m89.5m

Prepaid Expenses

12.7m9.4m16.6m

Inventories

42.2m34.3m31.4m27.1m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

87.9m88.7m97.4m93.3m90.6m84.9m89.9m81.2m148.9m

Accounts Receivable

113.2m121.1m123.7m119.1m116.6m142.6m4.8m118.3m102.5m94.1m

Prepaid Expenses

9.5m9.8m10.1m11.5m12.5m11.3m14.0m16.2m

Inventories

38.9m38.2m33.4m35.9m33.3m31.9m28.1m28.1m30.8m24.6m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

21.8m131.1m4.6m(53.1m)

Depreciation and Amortization

48.3m54.4m73.0m35.8m

Inventories

(1.2m)7.9m8.0m2.2m

Accounts Payable

(3.0m)4.0m1.1m(1.2m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

81.1m113.2m124.6m(700.0k)1.9m8.8m(20.6m)(28.9m)(144.1m)(39.5m)

Depreciation and Amortization

13.2m26.3m39.3m18.3m36.3m54.6m18.2m36.4m54.3m18.4m

Inventories

3.3m4.1m8.9m3.5m6.1m7.4m3.1m2.6m2.4m

Accounts Payable

400.0k3.0m(2.0m)(8.4m)(300.0k)(8.1m)(9.3m)(11.3m)(2.1m)300.0k
USDFY, 2017

Revenue/Employee

321.4k

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.6 x
Show all financial metrics

Myriad Genetics Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Patients Tested to Date

2 m3 m3 m

Products

11

Publications to Date

1 k

Countries

143
Show all operating metrics

Myriad Genetics Acquisitions / Subsidiaries

Company NameDateDeal Size
Myriad Women’s HealthMay 29, 2018$408.6 m
Myriad NeuroscienceAugust 03, 2016$351.6 m
Sividon DiagnosticsMay 31, 2016$56 m
Privatklinik Dr. Robert SchindlbeckFebruary 27, 2015$20.1 m
Crescendo BioscienceFebruary 04, 2014$270 m
Rules-Based MedicineApril 27, 2011$80 m
Javelin PharmaceuticalsDecember 18, 2009$95 m
NaturNorth TechnologiesApril 10, 2008
AssureRx Canada, Ltd
Assurex Health, Inc.
Show more

Myriad Genetics Revenue Breakdown

Embed Graph

Myriad Genetics revenue breakdown by business segment: 7.2% from Pharmaceutical and Clinical Services and 92.8% from Molecular Diagnostic Testing

Myriad Genetics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

SecurityScorecard logo

Myriad Genetics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Myriad Genetics Online and Social Media Presence

Embed Graph

Myriad Genetics Company Culture

  • Overall Culture

    B

    70/100

  • CEO Rating

    D+

    61/100

  • Compensation

    B

    74/100

Learn more on Comparably

Myriad Genetics News and Updates

Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Goldman Sachs 2021 Virtual Gl…

Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) -- On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Cas…

Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization…

Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health Business

New President Brings Proven Track Record in Women’s Health; Direct to Physician and Direct to Patient Commercial Expertise New President Brings Proven Track Record in Women’s Health; Direct to Physician and Direct to Patient Commercial Expertise

Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

Study Is First to Validate New Polygenic Risk Assessment for All; Company Aims to Improve Access and Reduce Disparities in Genetic Testing Study Is First to Validate New Polygenic Risk Assessment for All; Company Aims to Improve Access and Reduce Disparities in Genetic Testing

Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference

SALT LAKE CITY, May 05, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Bank of America Securiti…
Show more

Myriad Genetics Blogs

My Myriad: Gwen Turner, Diversity, Equity, Inclusion, and Engagement

At Myriad Genetics, we’re proud to deliver clinically actionable genetic information in the areas of oncology, women’s health, and mental health.… The post My Myriad: Gwen Turner, Diversity, Equity, Inclusion, and Engagement appeared first on Myriad Genetics, Inc..

ASCO 2021 Preview: Making Breast Cancer Risk Assessment More Inclusive

We are already looking forward to one of the biggest cancer-focused conferences of the year: the annual meeting of the American… The post ASCO 2021 Preview: Making Breast Cancer Risk Assessment More Inclusive appeared first on Myriad Genetics, Inc..

Health. Illuminated.

Leading the Way to the Future of Genetic Testing and Precision Medicine Thirty years ago, Myriad Genetics played a pivotal role… The post Health. Illuminated. appeared first on Myriad Genetics, Inc..

Thank a Laboratory Professional This Week!

This week is Medical Laboratory Professionals Week, and that means the Myriad Genetics team is celebrating! Now in its 45th year, “Lab Week,” as it’s… The post Thank a Laboratory Professional This Week! appeared first on Myriad Genetics, Inc..

Boldly Going Exactly Where I Was Meant to Be!

Since joining Myriad Genetics two decades ago, I’ve had five different roles across various departments––and the company has nurtured my dream… The post Boldly Going Exactly Where I Was Meant to Be! appeared first on Myriad Genetics, Inc..

Join Us in Raising Awareness of Colorectal Cancer

You hear a lot about certain types of cancer. In fact, you can probably name some famous people who have had… The post Join Us in Raising Awareness of Colorectal Cancer appeared first on Myriad Genetics, Inc..
Show more

Myriad Genetics Frequently Asked Questions

  • When was Myriad Genetics founded?

    Myriad Genetics was founded in 1991.

  • Who are Myriad Genetics key executives?

    Myriad Genetics's key executives are Bryan Riggsbee, Paul J. Diaz and Patrick Burke.

  • How many employees does Myriad Genetics have?

    Myriad Genetics has 2,600 employees.

  • What is Myriad Genetics revenue?

    Latest Myriad Genetics annual revenue is $299.8 m.

  • What is Myriad Genetics revenue per employee?

    Latest Myriad Genetics revenue per employee is $115.3 k.

  • Who are Myriad Genetics competitors?

    Competitors of Myriad Genetics include Asuragen, Progenity and Foundation Medicine.

  • Where is Myriad Genetics headquarters?

    Myriad Genetics headquarters is located at 320 Wakara Way, Salt Lake City.

  • Where are Myriad Genetics offices?

    Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations.

  • How many offices does Myriad Genetics have?

    Myriad Genetics has 13 offices.